GI Esophageal / Gastric

Localized

<table>
<thead>
<tr>
<th>HER 2+</th>
<th>HER 2-</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st Line</td>
<td>1st Line</td>
</tr>
<tr>
<td>2nd Line</td>
<td>2nd Line</td>
</tr>
</tbody>
</table>

**Localized**

- IRB #12071
  *A Pilot Study Using a Novel Imaging of Lymph Nodes in Patients with Locally Advanced Esophageal Cancer Using Ferumoxytol Enhanced MRI*

**Metastatic**

- No Trials Currently Available
- IRB #15349
  *Keynote-181 A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First Line Standard Therapy*
- IRB #15706
  *EMR100070-007: Phase III open-label, of maintenance therapy with avelumab versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction*
- IRB #15349
  *Keynote-181 A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First Line Standard Therapy*

12/30/2016

www.ohsu.edu/cancer